CD274 and triple-negative breast carcinoma: Based on the outcome of a phase 3 IMpassion130 trial which demonstrated that an atezolizumab plus nab-paclitaxel clinical regimen prolonged progression-free survival among patients with metastatic triple-negative breast cancer, atezolizumab received accelerated FDA approval in March 2019 for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 [7,8].